Sep 30, 2019 3:00am EDT Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019
Sep 23, 2019 7:05am EDT Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019
Sep 04, 2019 7:05am EDT IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation
Aug 08, 2019 5:05pm EDT IMV Inc. Announces Second Quarter 2019 Financial Results and Provides Company Update
Jul 25, 2019 3:22pm EDT IMV Inc. to Announce Second Quarter 2019 Results and Host a Conference Call and Webcast on August 9, 2019
Jun 04, 2019 7:05am EDT IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019
Jun 01, 2019 2:15pm EDT IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival
